Like Idenix, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has a pipeline of hepatitis C drugs. The most valuable, perhaps, is ACH-3422, a nucleotide NS5B polyermase inhibitor. The conventional thinking is that so-called “nucs” are the linchpin of hepatitis C combination therapy. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) weekly performance is 52.88%. On last trading day company shares ended up $4.25. Analysts mean target price for the company is $5.44. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average is 48.12%.
Gilead Sciences, Inc. (NASDAQ:GILD) announced that its corporate presentation will be webcast from two upcoming investor conferences: the William Blair 34th Annual Growth Stock Conference in Chicago and the Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes. Gilead Sciences, Inc. (NASDAQ:GILD) shares fell -4.11% in last trading session and ended the day on $79.00. GILD Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly performance is -1.53%.
MannKind Corporation (NASDAQ:MNKD) is anticipating the approval of its diabetes treatment drug – Afrezza, by July 15, 2014! FDA’s advisory committee earlier recommended the use of this drug to treat Type1 and Type2 Diabetes. However, the regulatory authority delayed its Prescription Drug User Fee Act or PDUFA review by July 15. MannKind Corporation (NASDAQ:MNKD) shares moved up 4.09% in last trading session and was closed at $10.70, while trading in range of $10.40. MannKind Corporation (NASDAQ:MNKD) year to date performance is 105.77%.
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American Diabetes Association’s (ADA) 74th Scientific Sessions taking place June 13-17, 2014 in San Francisco, California. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended the last trading day at $5.97. Company weekly volatility is calculated as 3.28% and price to cash ratio as 5.11. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showed a negative weekly performance of -1.49%.
Ariad Pharmaceuticals (NASDAQ:ARIA)‘s stock had its “positive” rating reiterated by equities researchers at Jefferies Group in a research report issued on Monday.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -4.61%. On last trading day company shares ended up $6.62. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average is -6.13%.